KLOW Protocol: KPV, BPC-157, TB-500 and GHK-Cu

No trial has tested the combination. The dosing site that ranks for the term states it plainly: no published clinical trial has evaluated the four-peptide KLOW combination together, and the circulated doses are extrapolated from single-compound research and community protocols, not validated for the blend.^[10]

BPC-157 has the most human data of the four, and it is still thin. A 2025 narrative review found only three human pilot studies, for intraarticular knee pain, interstitial cystitis, and intravenous safety, with no adverse effects reported but no large trials.^[4] A 2025 systematic review screened 544 articles and included 36 studies, of which 35 were preclinical and 1 was clinical, and found no clinical safety data.^[6]

The interstitial cystitis pilot injected a total of 10 mg of BPC-157 around the bladder wall during a single cystoscopy in 12 women (trial dose, not a recommendation, PMID 39325560); 10 of the 12 rated the result at 100 percent, with no adverse events, and there was no control group.^[8] The knee-pain report was a retrospective chart review of 17 patients that stated no dose in its abstract, used no validated outcome tool, and had no control group.^[7] BPC-157 is reported to have a half-life of under 30 minutes and to be cleared by the kidneys.^[6]

The human "TB-500" record is really a thymosin beta 4 record. Full-length thymosin beta 4 has a genuine trial history: eye-drop trials such as ARISE-3 enrolled hundreds, and healthy-volunteer safety studies used single intravenous doses from 0.5 to 25 mcg per kg (trial dose, not a recommendation, full-length thymosin beta 4 and not the TB-500 fragment, ClinicalTrials.gov NCT04555824). None of that used the TB-500 fragment.^[14]

GHK-Cu and KPV human trial evidence is thin to absent. The one registered GHK-Cu study found here is a recruiting split-wound trial of a topical 0.1 percent gel with no results, and it shares a sponsor and identical dates with a registry record that describes itself as fictional, so its provenance is unverified.^[15] No registered trial names KPV, and the FDA reports no human exposure data for KPV by any route.^[14][9] Separately, one completed dietary-supplement study by the product's seller, which has published no results, used oral BPC-157 gummies at 500 mcg per serving, two gummies daily for 8 weeks (trial dose, not a recommendation, ClinicalTrials.gov NCT07752381).^[17]

Most of what is known about BPC-157 comes from rats, and reviewers say so directly: the majority of studies have been in small rodent models, and efficacy is not confirmed in humans.^[2] The routes named for that animal work are intraperitoneal, per-oral, or local.^[19] No fetched abstract states a dose figure for any of it, and one review mentions only the same dose range without ever giving a number.^[3] The claimed preclinical breadth covers skin, muscle, tendon, ligament, bone, gastrointestinal ulcers, corneal ulcer, and fistulas in rats.^[20][3]

For KPV, for the TB-500 fragment, and for GHK-Cu, the single permitted literature search returned no animal study, so this page makes no animal-evidence claim for those three.

BPC-157 reviews describe few reported side effects and note that a lethal dose was not reached in the cited animal work.^[1][3] The interstitial cystitis pilot reported no adverse events, and a 2025 review reported none across the three human BPC-157 pilot studies.^[8][4] But the same systematic review that found no clinical safety data warns that adverse effects are possible from unregulated manufacturing and contamination, and that the absence of reported harm reflects an absence of human data, not a safety finding.^[6]

For KPV, the TB-500 fragment, and GHK-Cu, no side-effect data of any kind was found in this research. The FDA's stated concern for all four is manufacturing-related: immunogenicity for certain routes of administration, aggregation, and peptide-related impurities.^[9]

None of the four is an FDA-approved drug. The FDA lists all four on its compounding page, in the table of bulk drug substances that were nominated for compounding and then withdrawn by the nominators, with the page current as of 22 April 2026.^[9] For KPV and for the TB-500 fragment, the FDA states it has identified no human exposure data by any route.^[9]

Anti-doping status is contested in the literature we could read. One 2025 review says BPC-157 was temporarily banned by the World Anti-Doping Agency in 2022 and is not currently listed, while a 2025 systematic review describes its use as banned in professional sport.^[1][6]WADA's own list could not be retrieved in this research, so this page does not assert a current WADA status.

The KLOW search results are vendor and clinic pages. One leading vendor, True Research Labs, states its blend is tested to at least 99 percent purity by independent third-party HPLC and mass spectrometry with batch-level endotoxin screening, and says full reports are available; its certificates page, as fetched on 2026-09-06, published no downloadable report and linked to no individual document.^[11] The same vendor states it does not manufacture and sources from third-party suppliers.^[11] Its domain was registered in January 2026, roughly seven months before this research, according to the authoritative .com registry.^[21] Every vendor page fetched carries a research-use-only disclaimer, and a US clinic page notes that this labeling is a regulatory status, not a quality endorsement, and means no clinician has evaluated the compound for a given person.^[11][12]

A registry integrity note: the only ClinicalTrials.gov record found that names TB-500 as the fragment opens by stating it is a fictional example, and two further records, for a BPC-157 hamstring trial and a GHK-Cu gel trial, share that record's sponsor and dates, so their provenance is unverified. None of the three should be read as evidence.^[15]

In Vietnam, the largest pharmacy chain, Long Chau, returned no GHK-Cu and no BPC-157 product when searched on 2026-09-06; the searches completed normally and matched nothing, a genuine absence on that site rather than a blocked request.^[16] No price and no product page could be recorded for any of the four in Vietnam, and Vietnamese drug-registration status could not be verified because the government sources were unreachable from this network, which is a tooling limit, not evidence that the compounds are unregistered.